Phenylketonuria Market

Phenylketonuria (PKU) is a rare inherited disorder that causes an amino acid called phenylalanine to build up in the body. Phenylketonuria is caused by a defect in the gene that helps create the enzyme needed to break down phenylalanine. It can eventually lead to serious health problems.

Phenylketonuria Symptoms

Various symptoms associated with Phenylketonuria include musty odor in the breath, skin or urine, seizures, skin rashes (eczema), abnormally small head (microcephaly), behavioral, emotional, and social problems, hyperactivity, intellectual disability, delayed development, and psychiatric disorders.

Phenylketonuria Epidemiological Segmentation 

The Epidemiological Segmentation of Phenylketonuria in 7MM from 2018 to 2030 is segmented into:-

  • Diagnosed prevalent cases of Phenylketonuria
  • Age-specific diagnosed prevalent cases of Phenylketonuria
  • Severity-specific diagnosed prevalent cases of Phenylketonuria
  • Phenylketonuria diagnosed prevalent cases by mutation type 

Phenylketonuria Epidemiological Insights Observed in 2020

  • The total number of Phenylketonuria diagnosed prevalent cases in 7MM was 49,887.
  • The number of Phenylketonuria cases in Germany was found to be 8,317.
  • The number of Phenylketonuria cases in France was observed to be 7,523.
  • The number of Phenylketonuria cases in the United Kingdom was found to be 6,564.
  • The number of Phenylketonuria cases in Spain was observed to be 2,490.
  • For the Severity-specific Diagnosed Prevalent Cases of Phenylketonuria, classic Phenylketonuria cases were found to be 24,164, whereas mild Phenylketonuria cases were observed to be 14,752 and mild hyperphenylalaninemia cases were 10,971.

Phenylketonuria Market

The Phenylketonuria therapeutic market is expected to change in the 7MM during the study period (2018–2030).

Phenylketonuria Emerging Drugs

The emerging drugs of the Phenylketonuria market are

  • SYNB-1618
  • CNSA-001/PTC923, and others

Phenylketonuria Key Players

The key players working in the Phenylketonuria market are 

  • Synlogic
  • Censa Pharmaceuticals
  • PTC Therapeutics, and others